Company news

Metagenomi Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Metagenomi Therapeutics to Present Preclinical Data Supporting MGX-001, a Potential One-Time Therapy for Hemophilia A, in Oral Presentation at 68th American Society of Hematology Annual Meeting

November 4, 2026

Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference

October 13, 2026

Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

September 1, 2026

Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

August 10, 2026

Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference

May 28, 2026

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

May 11, 2026

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

April 15, 2026

Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results

March 4, 2026

Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference

February 23, 2026

Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook

January 12, 2026

Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference

December 1, 2025

Metagenomi to Present at Jefferies Global Healthcare Conference in London

November 17, 2025

Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates

November 11, 2025

Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development

November 11, 2025

Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results

August 12, 2025

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

August 11, 2025

Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025

May 14, 2025

Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

May 13, 2025

Metagenomi to Present at Upcoming Scientific Meetings

May 2, 2025

Metagenomi Reports Business Updates and Full Year 2024 Financial Results

March 17, 2025

Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems

March 13, 2025

Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones

January 15, 2025

Metagenomi Announces New Appointment to its Board of Directors

January 14, 2025

Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting

December 8, 2024

Metagenomi Reports Business Updates and Third Quarter 2024 Financial Results

November 12, 2024

Metagenomi To Present New Preclinical Hemophilia A Data at American Society of Hematology (ASH) 66th Annual Meeting

November 4, 2024

Metagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months

September 2, 2024

Metagenomi Presents AI-Enabled Advancements of SMART Editing Platform at the Cold Spring Harbor Laboratory CRISPR Frontiers Conference

August 28, 2024

Metagenomi Reports Business Updates and Second Quarter 2024 Financial Results

August 13, 2024

Metagenomi Reports Business Updates and Full Year 2023 Financial Results

March 26, 2024

Metagenomi Announces Closing of Initial Public Offering

February 12, 2024

Calls

Decks

The 5 newest of 11 decks. Every deck is listed under its year.